SMAD2 and lung adenocarcinoma: Similarly, Lin et al. reported that miR-155-5p reduced the metastatic potential of lung adenocarcinoma cells by targeting SMAD2, while Yao et al. identified SPOCK1 as a direct downstream target of miR-155-5p.